<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Exp Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Exp Neurobiol</journal-id>
<journal-id journal-id-type="publisher-id">EN</journal-id>
<journal-title-group>
<journal-title>Experimental Neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1226-2560</issn>
<issn pub-type="epub">2093-8144</issn>
<publisher>
<publisher-name>The Korean Society for Brain and Neural Science</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28680297</article-id>
<article-id pub-id-type="pmc">5491580</article-id>
<article-id pub-id-type="doi">10.5607/en.2017.26.3.122</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Altered GABAergic Signaling in Brain Disease at Various Stages of Life</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Yoo Sung</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yoon</surname>
<given-names>Bo-Eun</given-names>
</name>
<xref ref-type="aff" rid="A1"></xref>
</contrib>
</contrib-group>
<aff id="A1">Department of Molecular Biology, Dankook University, Cheonan 31116, Korea.</aff>
<author-notes>
<corresp>To whom correspondence should be addressed. TEL: 82-41-550-3694, FAX: 82-41-559-7941, <email>boeunyoon@dankook.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>5</month>
<year>2017</year>
</pub-date>
<volume>26</volume>
<issue>3</issue>
<fpage>122</fpage>
<lpage>131</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>3</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>06</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © Experimental Neurobiology 2017.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0">http://creativecommons.org/licenses/by-nc/4.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>In the healthy brain, gamma-aminobutyric acid (GABA) is regulated by neurons and glia. This begs the question: what happens in the malfunctioning brain? There are many reasons why diseases occur, including genetic mutations, systemic problems, and environmental influences. There are also many ways in which GABA can become dysregulated, such as through alterations in its synthesis or release, and changes in systems that respond to it. Notably, dysregulation of GABA can have a large impact on the brain. To date, few reviews have examined brain diseases in which dysregulation of GABA is implicated as an underlying factor. Accordingly, the time is ripe for investigating alterations in GABAergic signaling that may play a role in changes in neuronal activity observed in the major brain disorders that occur during various stages of life. This review is meant to provide a better understanding of the role of GABA in brain health and contributor to social problems from a scientific perspective.</p>
</abstract>
<kwd-group>
<kwd>GABA</kwd>
<kwd>brain disorder</kwd>
<kwd>lifespan</kwd>
<kwd>excitatory/inhibitory balance</kwd>
<kwd>neurodegenerative disease</kwd>
<kwd>neurodevelopmental disease</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>National Research Foundation of Korea</institution>
<institution-id institution-id-type="CrossRef">http://dx.doi.org/10.13039/501100003725</institution-id>
</institution-wrap>
</funding-source>
<award-id>NRF-2016M3C7A1905074</award-id>
<award-id>NRF-2016R1D1A1A02937398</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>The media and society are increasingly turning their attention to brain diseases. One reason that illnesses of the brain are currently in the spotlight is that, despite the increasing prevalence of brain diseases [<xref ref-type="bibr" rid="B1">1</xref><xref ref-type="bibr" rid="B2">2</xref>], information about them is limited. Psychiatric disorders, such as suicidal ideation, impulsive actions and addictive behaviors, are common societal problems [<xref ref-type="bibr" rid="B3">3</xref><xref ref-type="bibr" rid="B4">4</xref>]. In addition, as the population ages, the importance of healthy aging and concerns about neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), increasingly come to the fore [<xref ref-type="bibr" rid="B2">2</xref><xref ref-type="bibr" rid="B4">4</xref>]. The declining birth rate has also brought a renewed focus on children, since lower birth rates place a premium on treatments and therapies for neurodevelopmental disorders, such as attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASDs) [<xref ref-type="bibr" rid="B5">5</xref><xref ref-type="bibr" rid="B6">6</xref>]. It is also important to bear in mind that brain disorders can occur at different stages of life, and have accordingly been classified into three age categories—early, mature and later stages—based on studies performed in 2016 by the National Institute of Mental Health (NIMH) [<xref ref-type="bibr" rid="B7">7</xref><xref ref-type="bibr" rid="B8">8</xref>]. Thus, for both individual and social reasons, a better understanding of brain diseases is of paramount importance.</p>
<p>The brain sends and receives information through electrical and chemical signaling. This electrochemical signaling, which is transmitted by many types of neurotransmitters [<xref ref-type="bibr" rid="B11">11</xref><xref ref-type="bibr" rid="B12">12</xref><xref ref-type="bibr" rid="B13">13</xref>], regulates various brain functions. Notably, this signaling is important for striking the appropriate balance between neuronal excitation (E) and inhibition (I) [<xref ref-type="bibr" rid="B9">9</xref>]. If this E/I balance is disrupted, it can lead to a variety of pathological changes in the brain [<xref ref-type="bibr" rid="B10">10</xref>].</p>
<p>In this review, we focus on the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), with the goal of shedding light on its contribution to a number of neural pathologies [<xref ref-type="bibr" rid="B14">14</xref>]. The aim of the review is to establish the role of GABA in basic brain function and identify GABA-related mechanisms of neural diseases that can have an impact from the cradle to the grave (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
</sec>
<sec>
<title>GABAERGIC SIGNALING IN PATHOLOGICAL STATES</title>
<p>GABAergic inhibition takes two forms: phasic and tonic. Tonic inhibition involves a persistent inhibitory current mediated by high-affinity perisynaptic or extrasynaptic GABA receptors that is initiated in response to ambient or extracellular GABA levels (<xref ref-type="fig" rid="F2">Fig. 2</xref>)[<xref ref-type="bibr" rid="B15">15</xref>]. Phasic activation of GABA receptors is important for controlling the rhythm of neuronal activities, whereas tonic activation of these receptors occurs mainly in glia, without the influence of neuronal activity [<xref ref-type="bibr" rid="B15">15</xref>]. The tonic current enables inhibition to be shunted so as to control the gain in neuronal excitability [<xref ref-type="bibr" rid="B16">16</xref>]. In addition, the effects of tonic GABAergic inhibition can be more subtle because they are mediated by GABA binding to high-affinity GABA receptors [<xref ref-type="bibr" rid="B17">17</xref>].</p>
<sec>
<title>GABA<sub>A</sub> receptor</title>
<p>The GABA<sub>A</sub> receptor is a ligand-gated ion channel that, when activated, mediates influx of chloride ions and induces hyperpolarization in postsynaptic neurons. GABA acts as an inhibitory neurotransmitter at this receptor [<xref ref-type="bibr" rid="B18">18</xref><xref ref-type="bibr" rid="B19">19</xref>]. The GABA<sub>A</sub> receptor is composed of five subunits, which can be combined in a total of 19 ways. The various receptor combinations produce specific traits and are localized to different brain regions [<xref ref-type="bibr" rid="B20">20</xref>]. When mutations occur in GABA<sub>A</sub> receptor subunits, these receptors are unable to respond effectively to GABA released from presynaptic neurons and glia [<xref ref-type="bibr" rid="B18">18</xref>]. In addition, in some pathological conditions, the number of GABA<sub>A</sub> receptors is decreased [<xref ref-type="bibr" rid="B20">20</xref>], which has an effect similar to that observed with some mutations. GABA<sub>A</sub> receptors can be divided into two groups. Group one consists of GABA<sub>A</sub> receptors that respond to diazepam, a drug that binds to GABA<sub>A</sub> receptors and induces a calming behavioral effect. Group two receptors, referred to as GABA<sub>C</sub> receptors, are insensitive to diazepam. The fact that GABA<sub>A</sub> receptors can be subdivided into receptors that respond to diazepam or not means that the drugs used to treat diseases linked to GABA<sub>A</sub> receptors must be carefully selected [<xref ref-type="bibr" rid="B21">21</xref>].</p>
</sec>
<sec>
<title>GABA<sub>B</sub> receptor</title>
<p>The GABA<sub>B</sub> receptor is a metabotropic G-protein-coupled receptor [<xref ref-type="bibr" rid="B22">22</xref>] that serves a secondary messenger function in GABAergic signaling. Because activation of GABA<sub>A</sub> receptors requires postsynaptic G-protein activation, postsynaptic GABA<sub>B</sub> receptors increase the activity of extrasynaptic GABA<sub>A</sub> receptors. Presynaptic GABA<sub>B</sub> receptors activate the ambient form of GABA in the synapse, thereby increasing the total amount of GABA available, which in turn activates the GABA<sub>A</sub> receptor [<xref ref-type="bibr" rid="B23">23</xref>]. GABA<sub>B</sub> receptors can be divided into two groups. Receptors in the first are referred to as GABA<sub>B1</sub>, whereas those in the second are referred to as GABA<sub>B2</sub>. GABA<sub>B1</sub> activates neurons, and GABA<sub>B2</sub> is involved in signaling and membrane targeting [<xref ref-type="bibr" rid="B24">24</xref>]. The GABA<sub>B1</sub> receptor can be further subdivided into GABA<sub>B1a</sub> and GABA<sub>B1b</sub> subtypes. GABA<sub>B1a</sub> contains a specific domain called “sushi,” which causes localization of GABA<sub>B1a</sub> to the presynaptic terminals of excitatory synapses; it can also regulate glutamate release. In contrast, GABA<sub>B1b</sub> receptors are found at postsynaptic terminals [<xref ref-type="bibr" rid="B24">24</xref>]. Evidence from GABA<sub>B1</sub>-knockout (KO) mice showing that neuronal differentiation and the number of neuronal progenitor cells are increased in these animals suggests that the GABA<sub>B</sub> receptor affects neurogenesis in adults [<xref ref-type="bibr" rid="B25">25</xref>]. The association of the GABA<sub>B</sub> receptor with neurogenesis is related to stress and emotional changes; these changes, in turn, affect hippocampal volume, which is closely associated with psychological problems [<xref ref-type="bibr" rid="B26">26</xref>].</p>
</sec>
<sec>
<title>GABA transporter</title>
<p>The GABA transporter (GAT) is expressed mainly on glial cells. There are four GABA transporters: GAT-1, GAT-2 and GAT-3, and betaine GABA transporter (BGT)-1. For the most part, we will focus on GAT-1 here as it accounts for the majority of GABA uptake in astrocytes [<xref ref-type="bibr" rid="B27">27</xref><xref ref-type="bibr" rid="B28">28</xref>], which are responsible for taking up extrasynaptic GABA (eGABA). GAT appears to be closely related to tonic GABA inhibition [<xref ref-type="bibr" rid="B29">29</xref>]. When GAT activation is reduced and the uptake of the eGABA is decreased, eGABA concentrations are maintained at high levels [<xref ref-type="bibr" rid="B30">30</xref>]. For this reason, GAT is an important player in the mechanism of action of GABA.</p>
</sec>
</sec>
<sec>
<title>EARLY STAGES OF LIFE</title>
<p>In the early stages of life, many parts of the brain and body are still adjusting to the environments that the newborn infants are encountering [<xref ref-type="bibr" rid="B31">31</xref>]. This implies that many disorders that occur at this stage of life might be cured naturally as the children grow up. Here, we describe the following early-stage brain disorders: ADHD, ASD, and epilepsy [<xref ref-type="bibr" rid="B32">32</xref>].</p>
<sec>
<title>ADHD</title>
<p>ADHD is characterized by inattention, hyperactivity, and impulsivity [<xref ref-type="bibr" rid="B33">33</xref>]. Almost 10% of all children 4–17 years of age are diagnosed with ADHD [<xref ref-type="bibr" rid="B34">34</xref>]. ADHD may be caused by intense stress early in life that induces changes in the nervous system [<xref ref-type="bibr" rid="B35">35</xref>]. Since patients with ADHD lose control over their behavior, it is thought that ADHD is related to alterations in the brain inhibitory system, in particular, the inhibitory neurotransmitter GABA [<xref ref-type="bibr" rid="B34">34</xref>]. A previous study suggested that ADHD is related to the dopaminergic system and specifically to dopamine receptor 1 (DAP1) [<xref ref-type="bibr" rid="B36">36</xref>]. Although it has not yet been possible to definitively link this to GABA, numerous studies to date have focused on the GABA receptors, GABA<sub>A</sub> and GABA<sub>B</sub>. An examination of GABA<sub>A</sub> receptor variants has shown that polymorphisms in the X-linked <italic>GABRA3</italic> gene and the <italic>GABRB3</italic> gene account for about 1.4% of the variance in ADHD [<xref ref-type="bibr" rid="B37">37</xref>]. It has also been show that expression of various GABA<sub>A</sub> receptor subunits is decreased in ADHD [<xref ref-type="bibr" rid="B37">37</xref>]. Interestingly, ADHD is usually co-morbid with other diseases, such as ASD. A genetic study of ADHD and ASD family groups revealed that the <italic>GABRQ</italic> gene, which encodes a GABA<sub>A</sub> receptor subunit, as well as <italic>GABRA3</italic> , are associated with both ADHD and ASD [<xref ref-type="bibr" rid="B38">38</xref>]. The literature also suggests that glutamate levels are related to the intensity of ADHD traits, such as inattention and hyperactivity. However, recent genome-wide association studies (GWAS) and proteomic studies failed to identify polygenetic differences that affect glutamate or GABA between healthy controls and patients [<xref ref-type="bibr" rid="B39">39</xref>]. Additional genes that have yet to be identified may also be associated with ADHD [<xref ref-type="bibr" rid="B39">39</xref>]. A study performed on spontaneously-hypertensive rats (SHRs), a widely used animal model of ADHD, showed that the GABA<sub>A</sub> receptor is sensitive to stressors, especially in the hippocampus [<xref ref-type="bibr" rid="B35">35</xref>]. GABA receptor variants may result in alterations in GABAergic signaling, and steadily changed levels of GABA affect glutamate transmission and associated norepinephrine (NE) transmission [<xref ref-type="bibr" rid="B37">37</xref>]. In the latter case, stress may decrease hippocampal GABA<sub>A</sub> receptor numbers, which in turn would result in changes in NE levels. This decrease in tonic GABA and increase in NE found in SHRs may explain the abnormalities observed in ADHD [<xref ref-type="bibr" rid="B35">35</xref><xref ref-type="bibr" rid="B40">40</xref>].</p>
</sec>
<sec>
<title>Autism spectrum disorder</title>
<p>ASD is the second most common brain disease in children and, as mentioned above, it is related to ADHD [<xref ref-type="bibr" rid="B38">38</xref>]. Individuals with autism can display a range of symptoms; therefore, autism-related diseases are referred to as comprising a spectrum, a concept that incorporates Asperger's syndrome, pervasive developmental disorder, autistic disorder, and childhood disintegrative disorder [<xref ref-type="bibr" rid="B41">41</xref>]. Patients with diagnoses encapsulated by the umbrella term of ASD have specific traits, such as social deficits, impaired communication, and repetitive behaviors [<xref ref-type="bibr" rid="B42">42</xref>]. A comparison of ASD patients with healthy controls showed that the social deficits observed in ASD may be caused by hyperconnectivity in certain regions of the brain [<xref ref-type="bibr" rid="B43">43</xref>]. However, ASDs are mainly thought to be caused by an E/I imbalance, which may be induced by alterations in GABAergic signaling and GABA levels [<xref ref-type="bibr" rid="B44">44</xref>]. Significantly lower glutamate/GABA ratios have been found in patients with ASD [<xref ref-type="bibr" rid="B44">44</xref>]. Changes in GABA and glutamate may cause chronic developmental problems, reflecting the fact that these neurotransmitters are important for brain development and the maintenance of E/I balance during the early stages of life [<xref ref-type="bibr" rid="B43">43</xref><xref ref-type="bibr" rid="B44">44</xref>]. As described above, there are a variety of different GABA<sub>A</sub> receptor subtypes and subunits that can come together to form different types of GABA<sub>A</sub> receptors, each of which may have slightly different functions. However, GABA<sub>A</sub> receptors in the brains of patients with ASD lack diversity [<xref ref-type="bibr" rid="B45">45</xref>]. Such alterations in GABA<sub>A</sub> receptors may cause ASD and epileptic symptoms. Moreover, the density of GABA<sub>A</sub> and GABA<sub>B</sub> receptors in the cortex is decreased in patients with ASD [<xref ref-type="bibr" rid="B45">45</xref>]. Studies of transgenic models of ASD have identified mutations in the GABA<sub>A</sub> receptor, but not the GABA<sub>B</sub> receptor [<xref ref-type="bibr" rid="B44">44</xref>]. However, although the GABA<sub>B</sub> receptor has relatively little direct effect in ASD, it may impact the GABA<sub>A</sub> receptor. Thus, targeting the GABA<sub>B</sub> receptor may be an indirect way of treating ASD. In cases where output signals from GABAergic neurons are increased in normal mice, the GABA<sub>A</sub> receptor responds and produces impairments in long-term potentiation (LTP), highlighting the importance of the GABA<sub>A</sub> receptor [<xref ref-type="bibr" rid="B42">42</xref>]. Alterations in the secretion of GABA from GABAergic neurons differ from region to region in ASD. For example, in the subiculum, tonic GABA currents are decreased, whereas phasic currents are unaltered [<xref ref-type="bibr" rid="B42">42</xref>]. On the other hand, tonic and phasic GABA currents are both reduced in the amygdala [<xref ref-type="bibr" rid="B42">42</xref><xref ref-type="bibr" rid="B45">45</xref>].</p>
</sec>
<sec>
<title>Epilepsy</title>
<p>The overall prevalence of epilepsy is approximately 10 per 1000 individuals, but differs among countries and regions, and occurs more frequently in men than in women [<xref ref-type="bibr" rid="B46">46</xref>]. Epilepsy occurs in all age groups, although it most commonly occurs during infancy and childhood. Childhood epilepsy occurs at about twice the rate of adult epilepsy [<xref ref-type="bibr" rid="B47">47</xref>]. Since epilepsy is caused by the abnormal firing of neuronal systems, it can be detected by electroencephalography (EEG).</p>
<p>Several types of epilepsy exist, with the two main types being generalized seizures and focal seizures. Generalized seizures occur in both hemispheres, whereas focal seizures occur in specific areas of the brain. These two types of epilepsy can be further divided according to the duration and location of the seizures [<xref ref-type="bibr" rid="B48">48</xref>]. Epilepsy, like ASD, can also be considered a spectrum disorder, reflecting the number of different types of seizures and the variations in their etiology and comorbidities [<xref ref-type="bibr" rid="B49">49</xref><xref ref-type="bibr" rid="B50">50</xref>]. Differences in comorbidities associated with various types of epilepsy, age, sex, and seizure type influence the selection of drugs used to treat the condition [<xref ref-type="bibr" rid="B51">51</xref>]. Epilepsy that occurs at a young age usually exhibits ionic changes in the GABA<sub>A</sub> receptor and alterations in the E/I balance of the brain [<xref ref-type="bibr" rid="B52">52</xref>]. It has been shown that the loss of postsynaptic GABA<sub>A</sub> receptors and cation-chloride cotransporters (KCC2) is associated with tyrosine kinase B (TrkB), a receptor tyrosine kinase [<xref ref-type="bibr" rid="B52">52</xref>]. Enhanced activation of TrkB in mature neurons decreases surface expression of the GABA<sub>A</sub> receptor [<xref ref-type="bibr" rid="B52">52</xref>]. In addition, seizure-induced downregulation of KCC2 activity is dependent on posttranscriptional mechanisms, including cleavage by the protease calpain [<xref ref-type="bibr" rid="B53">53</xref>]. A number of studies have suggested that activation of calpain plays a role in epileptogenesis, as evidenced by its important effects on GABAergic signaling [<xref ref-type="bibr" rid="B52">52</xref><xref ref-type="bibr" rid="B53">53</xref>]. Adult epilepsy is usually just a partial form of epilepsy, and its primary causes include trauma, injury, and tumors [<xref ref-type="bibr" rid="B21">21</xref>].</p>
<p>Drugs that target GABA<sub>A</sub> receptors with high affinity [<xref ref-type="bibr" rid="B54">54</xref>] are used in the treatment of epilepsy. The structure and function of synaptic and extrasynaptic GABA<sub>A</sub> receptors provides numerous opportunities to create improved therapies for sleep, anxiety, stress, epilepsy, and other kinds of neuropsychiatric conditions.</p>
<p>GAT-1 also contributes to this disease. As noted above, GAT-1 is one of the major GABA transporters and is responsible for the uptake of synaptic GABA. Accordingly, GAT 1 at synapses represents an excellent target candidate for drugs designed to treat epilepsy [<xref ref-type="bibr" rid="B21">21</xref>].</p>
</sec>
</sec>
<sec>
<title>MATURE STAGE OF LIFE</title>
<p>Unlike the brains of infants and children, the brains of adults exhibit little neurogenesis or gliogenesis. As the number of newborn cells decreases and events that result in the loss of neurons and astrocytes increase, the volume of the brain decreases. This may be the cause of mood disorders later in life [<xref ref-type="bibr" rid="B54">54</xref>]. At this stage of life, GABA is inactivated by uptake into presynaptic terminals or glial cells, which is mediated by GATs [<xref ref-type="bibr" rid="B55">55</xref><xref ref-type="bibr" rid="B56">56</xref>].</p>
<sec>
<title>Depression</title>
<p>Depression is one of the most concerning psychiatric diseases in society today, owing to the high rates of suicide associated with it. The risk for depression increases with age, with the highest rates occurring in women in the 40–59 year age bracket. Depression, which can affect work life, home life and the survival of patients [<xref ref-type="bibr" rid="B57">57</xref>], may be caused by environmental factors, like childhood trauma or genetic problems [<xref ref-type="bibr" rid="B58">58</xref><xref ref-type="bibr" rid="B59">59</xref>]. Depression is not only a problem for individuals and their families, it also places an economic and obligatory burden on society [<xref ref-type="bibr" rid="B60">60</xref>].</p>
<p>Magnetic resonance imaging (MRI) studies have shown a reduction in hippocampal volume in depression [<xref ref-type="bibr" rid="B58">58</xref>]. Decreases in hippocampal volume are thought to alter the neural circuitry in the prefrontal cortex, amygdala, and structures that related to emotionality. Altered adult hippocampal neurogenesis may explain the cognitive deficits observed in depression [<xref ref-type="bibr" rid="B58">58</xref>]. GABAergic transmission plays an important role in the control of hippocampal neurogenesis and neural maturation, which are now established as cellular substrates of most, if not all, antidepressant therapies. Modest deficits in GABAergic transmission in GABA<sub>A</sub> receptor-deficient mice were found to be sufficient to cause behavioral, cognitive, neuroanatomical, and neuroendocrine phenotypes in an animal model of major depressive disorder (MDD) [<xref ref-type="bibr" rid="B61">61</xref>]. However, this does not mean that the GABA<sub>B</sub> receptor is not important in depression. Experiments carried out in GABA<sub>B1</sub> and GABA<sub>B2</sub> receptor knockout mice showed increased anxiety with an antidepressive phenotype [<xref ref-type="bibr" rid="B61">61</xref>]. Deficits in GABAergic transmission in the brain, discovered by proton magnetic resonance spectroscopy, are more severe in patients with unipolar than bipolar depression [<xref ref-type="bibr" rid="B61">61</xref>]. Decreased GABA levels have been found in the occipital cortex, anterior cingulate, and dorsomedial/dorsolateral prefrontal cortex of patients with MDD [<xref ref-type="bibr" rid="B61">61</xref>]. It has also been shown that GABA<sub>B</sub> receptor inhibitors produce antidepressant behavioral effects [<xref ref-type="bibr" rid="B62">62</xref>].</p>
</sec>
<sec>
<title>Anxiety</title>
<p>Given the role of GABAergic neurons in the acquisition, storage and extinction of fear memory [<xref ref-type="bibr" rid="B63">63</xref>], GABA<sub>A</sub> receptor modulators are used to treat anxiety. The fact that GABAergic deficits are observed in depressive disorders creates a compelling argument for the hypothesis that GABAergic neurons play a role in anxiety. Some specific subtypes of GABA<sub>A</sub> receptors are linked to signal transduction in interneurons [<xref ref-type="bibr" rid="B64">64</xref>]; therefore, these subtypes could play a role in mood, anxiety, and pain modulation. Thus, a reduction in GABA<sub>A</sub> receptors may underlie the deficits in GABAergic function observed in anxiety disorders and could modulate different forms of anxiety [<xref ref-type="bibr" rid="B61">61</xref><xref ref-type="bibr" rid="B65">65</xref>]. In patients with generalized anxiety disorder, the number of GABA<sub>A</sub> receptors is reduced in the temporal lobe [<xref ref-type="bibr" rid="B26">26</xref>]. Patients with post-traumatic stress disorder (PTSD) also have lower levels of GABA in the medial prefrontal cortex [<xref ref-type="bibr" rid="B66">66</xref>]. Moreover, patients with panic disorder have reduced GABA<sub>A</sub> receptor numbers in the frontal, temporal, and parietal cortices; the left hippocampus; and the precuneus [<xref ref-type="bibr" rid="B67">67</xref>]. These observations show that, in various types of anxiety, the GABA<sub>A</sub> receptor is reduced in different brain regions [<xref ref-type="bibr" rid="B67">67</xref>]. Since the GABA<sub>B</sub> receptor can contribute to inhibition by moderating the activity of the GABA<sub>A</sub> receptor at presynaptic and postsynaptic sites, the GABA<sub>B</sub> receptor may also play a role in anxiety. Many types of anxiety have been linked to the GABA<sub>B</sub> receptor, including PTSD, social and specific phobias, and generalized anxiety disorder [<xref ref-type="bibr" rid="B44">44</xref>].</p>
</sec>
</sec>
<sec>
<title>LATER STAGE OF LIFE</title>
<p>Today, there is an ever-increasing number of patients with neurodegenerative diseases, and diseases related to the brain are increasing steadily. The World Health Organization has predicted that two brain-related diseases—unipolar depression and cerebrovascular disease, which were ranked third and sixth, respectively in 2004—will rank among the top five diseases in the world in the year 2030 [<xref ref-type="bibr" rid="B2">2</xref><xref ref-type="bibr" rid="B68">68</xref>].</p>
<sec>
<title>Parkinson's disease</title>
<p>PD occurs at an annual rate of ~4.5–19 per 100,000 individuals [<xref ref-type="bibr" rid="B69">69</xref>]. This wide range is attributable to differences in age, sex, or other factors among sample groups. PD is well diagnosed globally, and the main symptoms include tremor and motor problems. Even though traditional methods of clinical diagnosis are sufficient for diagnosing PD, there are many ways of confirming the disease [<xref ref-type="bibr" rid="B2">2</xref>]. One method includes the detection of specific post-mortem changes in the expression of GABA<sub>A</sub> receptor subunit genes in the substantia nigra (SN) and caudate nucleus (CN) of patients with PD [<xref ref-type="bibr" rid="B70">70</xref>]. GABA<sub>A</sub> receptors, prominently including receptors containing the α4 subunit, are increased about 22-fold in these regions in PD [<xref ref-type="bibr" rid="B70">70</xref>]. Increases in the GABA<sub>A</sub> receptor also induce increased tonic inhibition by astrocytes [<xref ref-type="bibr" rid="B15">15</xref>]. Non-motor problems, like depression, also occur in PD, and have been found to involve the lateral habenula (LHb) [<xref ref-type="bibr" rid="B71">71</xref>]. Upregulation of GABA<sub>A</sub> receptors containing the α subunit and reduced release of GABA in the LHb appear to contribute to PD-related depression [<xref ref-type="bibr" rid="B71">71</xref>]. The density of GABA receptors varies between regions, with evidence for decreased GABA<sub>B</sub> receptors in the putamen and external globus pallidus (GP). Since characteristic functions of the receptor in various regions reflects differences in receptor subtypes, knowledge about the subtypes involved is important for the development of drug treatments [<xref ref-type="bibr" rid="B72">72</xref>].</p>
<p>Reactive astrocytes release inhibitory GABA into the brain, a process that has been described in brain or spinal cord trauma, epilepsy, stroke, and neurodegenerative diseases [<xref ref-type="bibr" rid="B70">70</xref><xref ref-type="bibr" rid="B72">72</xref>]. Reactive astrocytes have also been identified in PD, although the numbers of reactive astrocytes are low in PD [<xref ref-type="bibr" rid="B73">73</xref>].</p>
</sec>
<sec>
<title>Alzheimer's disease</title>
<p>AD is the best-known disease to affect the elderly, afflicting up to 50% of people over the age of 85. The hallmark of AD, which is a representative age-related neurodegenerative disease, is memory loss. In addition to the impact on the AD patient, families of AD sufferers experience an enormous burden [<xref ref-type="bibr" rid="B74">74</xref>].</p>
<p>It has been shown that GABA levels are decreased in patients with AD; however, in AD, GABA is synthesized by activated astrocytes and GAT3/4 is secreted. Increased GABA levels have also been described in patients with AD [<xref ref-type="bibr" rid="B73">73</xref>]. This latter study reported that increased activation of GAD67 induced the synthesis of GABA in astrocytes, and this GABA was secreted into synapses by reverse-functioning astrocytic GAT3/4 [<xref ref-type="bibr" rid="B75">75</xref>]. The release of GABA causes tonic inhibition of perforant path/dentate granule cell synapses [<xref ref-type="bibr" rid="B76">76</xref>]. Under pathological conditions, reactive astrocytes release more GABA through the bestrophin 1 (Best1) channel. This GABA may activate GABA<sub>A</sub> receptors in the extrasynaptic region and therefore confer inhibitory effects. Moreover, increased astrocytic GABA has been found in mouse brains, and this abnormal synthesis was found to be induced by monoamine oxidase B (MAOB) [<xref ref-type="bibr" rid="B77">77</xref>]. Cortical neurons adjacent to amyloid plaques exhibit a decrease in the number of GABAergic terminals. It has also been shown that the numbers of GABA<sub>A</sub> and GABA<sub>B</sub> receptors are increased in AD, and thus may become overactivated by the increased GABA levels observed in AD [<xref ref-type="bibr" rid="B78">78</xref>].</p>
<p>In summary, astrocytes exhibit increased expression of GAT, and synthesize and/or store and release GABA, which may increase tonic inhibition in their surrounding areas. In a mouse model of AD, increased tonic inhibition in the dentate gyrus was found following increases in astrocytic GABA. Taken together, these observations suggest that astrocytic GABA is an important player in the pathogenesis of AD [<xref ref-type="bibr" rid="B79">79</xref>].</p>
</sec>
</sec>
<sec sec-type="conclusions">
<title>CONCLUSIONS</title>
<p>The brain and brain diseases, long a subject of intense research interest, are increasingly a focus of the general population [<xref ref-type="bibr" rid="B80">80</xref><xref ref-type="bibr" rid="B81">81</xref><xref ref-type="bibr" rid="B82">82</xref><xref ref-type="bibr" rid="B83">83</xref><xref ref-type="bibr" rid="B84">84</xref><xref ref-type="bibr" rid="B85">85</xref>], possibly reflecting the high economic and societal burdens associated with brain diseases [<xref ref-type="bibr" rid="B86">86</xref>]. Brain disease can be classified according to age. About 15% of children in the USA experience neurodevelopmental disorders [<xref ref-type="bibr" rid="B87">87</xref>]; about 45% of adults experience mood disorders [<xref ref-type="bibr" rid="B87">87</xref>]; and about 50% of older adults have dementia, AD, or other neurodegenerative disorders [<xref ref-type="bibr" rid="B88">88</xref>]. In this review, we have taken a brief look at diseases that are linked to alterations in GABA receptors, such as receptor subunit mutations, reduced receptor function, reduced receptor number, and alterations in receptor density. These alterations, in turn, may lead to a reduction or increase in the effects of GABA at postsynaptic neurons.</p>
<p>GABA signaling may be a target for the treatment of diseases discussed in this review. Despite considerable research on the neuronal mechanisms and functions that underlie brain disease, studies on astrocytes and neuron-glia interactions in brain diseases are still limited. Moreover, although various analyses have been carried out on the role of GABA in various diseases, these experiments have necessarily been conducted at a relatively superficial level since a fundamental understanding of the mechanisms involved in each disease is lacking. To date, such studies have been limited to an investigation of the phenotypes associated with the overexpression or inhibition/KO of GABA and/or GABA receptors [<xref ref-type="bibr" rid="B89">89</xref><xref ref-type="bibr" rid="B90">90</xref>]. To gain a better understanding of the function of GABA in brain disorders, we must first have an understanding of its basic mechanisms. We hope that the introduction to GABA as a major inhibitory neurotransmitter and critical player in brain diseases provided by this review offers a more integrated view of the underlying scientific and social problems, and helps set the stage for more targeted investigations of detailed mechanisms.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGEMENTS</title>
<p>This study was supported by grants from the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT &amp; Future Planning (NRF-2016M3C7A1905074) and SGER program (NRF-2016R1D1A1A02937398) (B.E.Y).</p>
</ack>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grillner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Koroshetz</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Polachek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Poo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Sejnowski</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Worldwide initiatives to advance brain research</article-title>
<source/>Nat Neurosci
          <year>2016</year>
<volume>19</volume>
<fpage>1118</fpage>
<lpage>1122</lpage>
<pub-id pub-id-type="pmid">27571190</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="book">
<collab>World Health Organization</collab>
<source/>Neurological disorders: public health challenges
          <publisher-loc>Geneva</publisher-loc>
<publisher-name>World Health Organization</publisher-name>
<year>2006</year>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curtin</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hedegaard</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Increase in suicide in the United States, 1999-2014</article-title>
<source/>NCHS Data Brief
          <year>2016</year>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masten</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Faden</surname>
<given-names>VB</given-names>
</name>
<name>
<surname>Zucker</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Spear</surname>
<given-names>LP</given-names>
</name>
</person-group>
<article-title>A developmental perspective on underage alcohol use</article-title>
<source/>Alcohol Res Health
          <year>2009</year>
<volume>32</volume>
<fpage>3</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="pmid">23104443</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Leonardi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The burden of brain diseases in Europe</article-title>
<source/>Eur J Neurol
          <year>2003</year>
<volume>10</volume>
<fpage>471</fpage>
<lpage>477</lpage>
<pub-id pub-id-type="pmid">12940825</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Getahun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jacobsen</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Fassett</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Demissie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rhoads</surname>
<given-names>GG</given-names>
</name>
</person-group>
<article-title>Recent trends in childhood attention-deficit/hyperactivity disorder</article-title>
<source/>JAMA Pediatr
          <year>2013</year>
<volume>167</volume>
<fpage>282</fpage>
<lpage>288</lpage>
<pub-id pub-id-type="pmid">23338799</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="book">
<collab>Substance Abuse and Mental Health Services Administration (US)</collab>
<source/>Results from the 2008 national survey on drug use and health: national findings (office of applied studies, NSDUH series H-36, HHS publication No. SMA 09-4434)
          <publisher-loc>Rockville, MD</publisher-loc>
<publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>
<year>2009</year>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Baio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Van Naarden Braun</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bilder</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Charles</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Constantino</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Durkin</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Kurzius-Spencer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Pettygrove</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wingate</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Zahorodny</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yeargin-Allsopp</surname>
<given-names>M</given-names>
</name>
</person-group>
<collab>Centers for Disease Control and Prevention (CDC)</collab>
<article-title>Prevalence and characteristics of autism spectrum disorder among children aged 8 years--autism and developmental disabilities monitoring network, 11 sites, United States, 2012</article-title>
<source/>MMWR Surveill Summ
          <year>2016</year>
<volume>65</volume>
<fpage>1</fpage>
<lpage>23</lpage>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<collab>Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators</collab>
<collab>Centers for Disease Control and Prevention</collab>
<article-title>Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008</article-title>
<source/>MMWR Surveill Summ
          <year>2012</year>
<volume>61</volume>
<fpage>1</fpage>
<lpage>19</lpage>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yizhar</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Fenno</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Prigge</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>O'Shea</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Sohal</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Goshen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Finkelstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Paz</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Stehfest</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fudim</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ramakrishnan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huguenard</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hegemann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deisseroth</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Neocortical excitation/inhibition balance in information processing and social dysfunction</article-title>
<source/>Nature
          <year>2011</year>
<volume>477</volume>
<fpage>171</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="pmid">21796121</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schousboe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bak</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Waagepetersen</surname>
<given-names>HS</given-names>
</name>
</person-group>
<article-title>Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA</article-title>
<source/>Front Endocrinol (Lausanne)
          <year>2013</year>
<volume>4</volume>
<fpage>102</fpage>
<pub-id pub-id-type="pmid">23966981</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Danbolt</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>Glutamate as a neurotransmitter in the healthy brain</article-title>
<source/>J Neural Transm (Vienna)
          <year>2014</year>
<volume>121</volume>
<fpage>799</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="pmid">24578174</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tritsch</surname>
<given-names>NX</given-names>
</name>
<name>
<surname>Granger</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Mechanisms and functions of GABA co-release</article-title>
<source/>Nat Rev Neurosci
          <year>2016</year>
<volume>17</volume>
<fpage>139</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="pmid">26865019</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Charney</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Nemeroff</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>Neuropsychopharmacology: the fifth generation of progress
          <publisher-loc>Lippincott Williams &amp; Wilkins</publisher-loc>
<publisher-name>Philadelphia, PA</publisher-name>
<year>2002</year>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrant</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nusser</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors</article-title>
<source/>Nat Rev Neurosci
          <year>2005</year>
<volume>6</volume>
<fpage>215</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">15738957</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carver</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability</article-title>
<source/>Psychopharmacology (Berl)
          <year>2013</year>
<volume>230</volume>
<fpage>151</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="pmid">24071826</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stell</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Mody</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Receptors with different affinities mediate phasic and tonic GABA(A) conductances in hippocampal neurons</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>RC223</fpage>
<pub-id pub-id-type="pmid">12006605</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braat</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kooy</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders</article-title>
<source/>Neuron
          <year>2015</year>
<volume>86</volume>
<fpage>1119</fpage>
<lpage>1130</lpage>
<pub-id pub-id-type="pmid">26050032</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandolfo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetics of epilepsy</article-title>
<source/>Semin Neurol
          <year>2011</year>
<volume>31</volume>
<fpage>506</fpage>
<lpage>518</lpage>
<pub-id pub-id-type="pmid">22266888</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Moody</surname>
<given-names>OA</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Traynelis</surname>
<given-names>SF</given-names>
</name>
</person-group>
<article-title>Ionotropic GABA and glutamate receptor mutations and human neurologic diseases</article-title>
<source/>Mol Pharmacol
          <year>2015</year>
<volume>88</volume>
<fpage>203</fpage>
<lpage>217</lpage>
<pub-id pub-id-type="pmid">25904555</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Rugg-Gunn</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<chapter-title>Adult onset epilepsies</chapter-title>
<person-group person-group-type="editor">
<name>
<surname>Rugg-Gunn</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Smalls</surname>
<given-names>JE</given-names>
</name>
</person-group>
<source/>Epilepsy 2015 from channels to commissioning: a practical guide to epilepsy
          <publisher-loc>London</publisher-loc>
<publisher-name>International League Against Epilepsy (UK Chapter)</publisher-name>
<year>2011</year>
<fpage>149</fpage>
<lpage>156</lpage>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cryan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Kaupmann</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Don't worry ‘B’ happy!: a role for GABA(B) receptors in anxiety and depression</article-title>
<source/>Trends Pharmacol Sci
          <year>2005</year>
<volume>26</volume>
<fpage>36</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">15629203</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Spain</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Ransom</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Postsynaptic GABAB receptors enhance extrasynaptic GABAA receptor function in dentate gyrus granule cells</article-title>
<source/>J Neurosci
          <year>2013</year>
<volume>33</volume>
<fpage>3738</fpage>
<lpage>3743</lpage>
<pub-id pub-id-type="pmid">23447585</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pizzarelli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cherubini</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Alterations of GABAergic signaling in autism spectrum disorders</article-title>
<source/>Neural Plast
          <year>2011</year>
<volume>2011</volume>
<fpage>297153</fpage>
<pub-id pub-id-type="pmid">21766041</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giachino</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Barz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tchorz</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Tome</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gassmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bischofberger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bettler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>GABA suppresses neurogenesis in the adult hippocampus through GABAB receptors</article-title>
<source/>Development
          <year>2014</year>
<volume>141</volume>
<fpage>83</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="pmid">24284211</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The developmental origins of anxiety</article-title>
<source/>Nat Rev Neurosci
          <year>2004</year>
<volume>5</volume>
<fpage>545</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="pmid">15208696</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biederman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</name>
</person-group>
<article-title>Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type</article-title>
<source/>Am J Psychiatry
          <year>2000</year>
<volume>157</volume>
<fpage>816</fpage>
<lpage>818</lpage>
<pub-id pub-id-type="pmid">10784477</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Wiebking</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Northoff</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—a review of multimodal imaging studies</article-title>
<source/>Neurosci Biobehav Rev
          <year>2014</year>
<volume>47</volume>
<fpage>36</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">25066091</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kersanté</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rowley</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Pavlov</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gutièrrez-Mecinas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Semyanov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reul</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Linthorst</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>A functional role for both -aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus</article-title>
<source/>J Physiol
          <year>2013</year>
<volume>591</volume>
<fpage>2429</fpage>
<lpage>2441</lpage>
<pub-id pub-id-type="pmid">23381899</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YZ</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>YQ</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Fei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>TL</given-names>
</name>
</person-group>
<article-title>GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<fpage>e69883</fpage>
<pub-id pub-id-type="pmid">23922840</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogtay</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giedd</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Lusk</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Greenstein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vaituzis</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Nugent</surname>
<given-names>TF</given-names>
<suffix>3rd</suffix>
</name>
<name>
<surname>Herman</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Clasen</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Toga</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Dynamic mapping of human cortical development during childhood through early adulthood</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<fpage>8174</fpage>
<lpage>8179</lpage>
<pub-id pub-id-type="pmid">15148381</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bitsko</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Blumberg</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Pastor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ghandour</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Gfroerer</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Hedden</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Crosby</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Schieve</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Parks</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Brody</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Simile</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Baio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Avenevoli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>LN</given-names>
</name>
</person-group>
<collab>Centers for Disease Control and Prevention (CDC)</collab>
<article-title>Mental health surveillance among children--United States, 2005-2011</article-title>
<source/>MMWR Suppl
          <year>2013</year>
<issue>62</issue>
<fpage>1</fpage>
<lpage>35</lpage>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="book">
<collab>American Psychiatric Association</collab>
<source/>Diagnostic and statistical manual of mental disorders: DSM-5®
          <edition>5th ed</edition>
<publisher-loc>Washington, D.C.</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
<year>2013</year>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pastor</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Reuben</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Association between diagnosed ADHD and selected characteristics among children aged 4-17 years: United States, 2011-2013</article-title>
<source/>NCHS Data Brief
          <year>2015</year>
<fpage>201</fpage>
<pub-id pub-id-type="pmid">25974000</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterley</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Howells</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Evidence for reduced tonic levels of GABA in the hippocampus of an animal model of ADHD, the spontaneously hypertensive rat</article-title>
<source/>Brain Res
          <year>2013</year>
<volume>1541</volume>
<fpage>52</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="pmid">24161405</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garbutt</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>van Kammen</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>The interaction between GABA and dopamine: implications for schizophrenia</article-title>
<source/>Schizophr Bull
          <year>1983</year>
<volume>9</volume>
<fpage>336</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="pmid">6137869</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comings</surname>
<given-names>DE</given-names>
</name>
</person-group>
<article-title>Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders</article-title>
<source/>Ann N Y Acad Sci
          <year>2001</year>
<volume>931</volume>
<fpage>50</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">11462757</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naaijen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bralten</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poelmans</surname>
<given-names>G</given-names>
</name>
</person-group>
<collab>IMAGE consortium</collab>
<person-group person-group-type="author">
<name>
<surname>Glennon</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Franke</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Buitelaar</surname>
<given-names>JK</given-names>
</name>
</person-group>
<article-title>Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism</article-title>
<source/>Transl Psychiatry
          <year>2017</year>
<volume>7</volume>
<fpage>e999</fpage>
<pub-id pub-id-type="pmid">28072412</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharp</surname>
<given-names>SI</given-names>
</name>
<name>
<surname>McQuillin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gurling</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Genetics of attention-deficit hyperactivity disorder (ADHD)</article-title>
<source/>Neuropharmacology
          <year>2009</year>
<volume>57</volume>
<fpage>590</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">19715710</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sterley</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Howells</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>VA</given-names>
</name>
</person-group>
<article-title>Maternal separation increases GABA(A) receptor-mediated modulation of norepinephrine release in the hippocampus of a rat model of ADHD, the spontaneously hypertensive rat</article-title>
<source/>Brain Res
          <year>2013</year>
<volume>1497</volume>
<fpage>23</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="pmid">23276497</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsai</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Ghaziuddin</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>DSM-5 ASD moves forward into the past</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<fpage>321</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">23807202</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Excitation/inhibition imbalance in animal models of autism spectrum disorders</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<fpage>838</fpage>
<lpage>847</lpage>
<pub-id pub-id-type="pmid">27450033</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Supekar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>LQ</given-names>
</name>
<name>
<surname>Khouzam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gaillard</surname>
<given-names>WD</given-names>
</name>
<name>
<surname>Kenworthy</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Yerys</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Vaidya</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Brain hyperconnectivity in children with autism and its links to social deficits</article-title>
<source/>Cell Rep
          <year>2013</year>
<volume>5</volume>
<fpage>738</fpage>
<lpage>747</lpage>
<pub-id pub-id-type="pmid">24210821</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Ansary</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Al-Ayadhi</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders</article-title>
<source/>J Neuroinflammation
          <year>2014</year>
<volume>11</volume>
<fpage>189</fpage>
<pub-id pub-id-type="pmid">25407263</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heaney</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Kinney</surname>
<given-names>JW</given-names>
</name>
</person-group>
<article-title>Role of GABA(B) receptors in learning and memory and neurological disorders</article-title>
<source/>Neurosci Biobehav Rev
          <year>2016</year>
<volume>63</volume>
<fpage>1</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="pmid">26814961</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shakirullah</surname>
</name>
<name>
<surname>Ali</surname>
<given-names>N</given-names>
</name>
<name>
<surname>khan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nabi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The prevalence, incidence and etiology of epilepsy</article-title>
<source/>Int J Clin Exp Neurol
          <year>2014</year>
<volume>2</volume>
<fpage>29</fpage>
<lpage>39</lpage>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Featherstone</surname>
<given-names>V</given-names>
</name>
</person-group>
<source/>Epilepsy in children and young people
          <publisher-loc>Cerebra</publisher-loc>
<publisher-name>Carmarthen</publisher-name>
<year>2010</year>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carney</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Prowse</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
</person-group>
<article-title>Epilepsy syndromes in children</article-title>
<source/>Aust Fam Physician
          <year>2005</year>
<volume>34</volume>
<fpage>1009</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="pmid">16333482</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salpekar</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Key issues in addressing the comorbidity of attention deficit hyperactivity disorder and pediatric epilepsy</article-title>
<source/>Epilepsy Behav
          <year>2014</year>
<volume>37</volume>
<fpage>310</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="pmid">24835083</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jokiranta</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Sourander</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suominen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Timonen-Soivio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Sillanpää</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Epilepsy among children and adolescents with autism spectrum disorders: a population-based study</article-title>
<source/>J Autism Dev Disord
          <year>2014</year>
<volume>44</volume>
<fpage>2547</fpage>
<lpage>2557</lpage>
<pub-id pub-id-type="pmid">24803367</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shetty</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Upadhya</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>GABA-ergic cell therapy for epilepsy: advances, limitations and challenges</article-title>
<source/>Neurosci Biobehav Rev
          <year>2016</year>
<volume>62</volume>
<fpage>35</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">26748379</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaila</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ruusuvuori</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Seja</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Voipio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Puskarjov</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>GABA actions and ionic plasticity in epilepsy</article-title>
<source/>Curr Opin Neurobiol
          <year>2014</year>
<volume>26</volume>
<fpage>34</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">24650502</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Carlsen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>González</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>A calpain inhibitor ameliorates seizure burden in an experimental model of temporal lobe epilepsy</article-title>
<source/>Neurobiol Dis
          <year>2017</year>
<volume>102</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">28237317</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maletic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Raison</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Integrated neurobiology of bipolar disorder</article-title>
<source/>Front Psychiatry
          <year>2014</year>
<volume>5</volume>
<fpage>98</fpage>
<pub-id pub-id-type="pmid">25202283</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Unichenko</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kirischuk</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luhmann</surname>
<given-names>HJ</given-names>
</name>
</person-group>
<article-title>GABA transporters control GABAergic neurotransmission in the mouse subplate</article-title>
<source/>Neuroscience
          <year>2015</year>
<volume>304</volume>
<fpage>217</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="pmid">26232716</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Díez-Sampedro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Richerson</surname>
<given-names>GB</given-names>
</name>
</person-group>
<article-title>Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1</article-title>
<source/>Neuron
          <year>2007</year>
<volume>56</volume>
<fpage>851</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="pmid">18054861</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pratt</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Brody</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Depression in the U.S. household population, 2009-2012</article-title>
<source/>NCHS Data Brief
          <year>2014</year>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahay</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hen</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Adult hippocampal neurogenesis in depression</article-title>
<source/>Nat Neurosci
          <year>2007</year>
<volume>10</volume>
<fpage>1110</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="pmid">17726477</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gilman</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Kawachi</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fitzmaurice</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Buka</surname>
<given-names>SL</given-names>
</name>
</person-group>
<article-title>Family disruption in childhood and risk of adult depression</article-title>
<source/>Am J Psychiatry
          <year>2003</year>
<volume>160</volume>
<fpage>939</fpage>
<lpage>946</lpage>
<pub-id pub-id-type="pmid">12727699</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>The costs of depression</article-title>
<source/>Psychiatr Clin North Am
          <year>2012</year>
<volume>35</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="pmid">22370487</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luscher</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Sahir</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>The GABAergic deficit hypothesis of major depressive disorder</article-title>
<source/>Mol Psychiatry
          <year>2011</year>
<volume>16</volume>
<fpage>383</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="pmid">21079608</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couve</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moss</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Pangalos</surname>
<given-names>MN</given-names>
</name>
</person-group>
<article-title>GABAB receptors: a new paradigm in G protein signaling</article-title>
<source/>Mol Cell Neurosci
          <year>2000</year>
<volume>16</volume>
<fpage>296</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="pmid">11085869</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalueff</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Role of GABA in anxiety and depression</article-title>
<source/>Depress Anxiety
          <year>2007</year>
<volume>24</volume>
<fpage>495</fpage>
<lpage>517</lpage>
<pub-id pub-id-type="pmid">17117412</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Möhler</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The GABA system in anxiety and depression and its therapeutic potential</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<fpage>42</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">21889518</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalueff</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Role of GABA in memory and anxiety</article-title>
<source/>Depress Anxiety
          <year>1996-1997</year>
<volume>4</volume>
<fpage>100</fpage>
<lpage>110</lpage>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trousselard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lefebvre</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Caillet</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Andruetan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>de Montleau</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Denis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Canini</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Is plasma GABA level a biomarker of post-traumatic stress disorder (PTSD) severity? A preliminary study</article-title>
<source/>Psychiatry Res
          <year>2016</year>
<volume>241</volume>
<fpage>273</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="pmid">27208514</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fatemi</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Folsom</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism</article-title>
<source/>Schizophr Res
          <year>2015</year>
<volume>167</volume>
<fpage>42</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">25432637</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="book">
<collab>World Health Organization</collab>
<source/>The global burden of disease: 2004 update
          <publisher-loc>World Health Organization</publisher-loc>
<publisher-name>Geneva</publisher-name>
<year>2008</year>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Lau</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Breteler</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Epidemiology of Parkinson's disease</article-title>
<source/>Lancet Neurol
          <year>2006</year>
<volume>5</volume>
<fpage>525</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="pmid">16713924</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luchetti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huitinga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Swaab</surname>
<given-names>DF</given-names>
</name>
</person-group>
<article-title>Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis</article-title>
<source/>Neuroscience
          <year>2011</year>
<volume>191</volume>
<fpage>6</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">21514366</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>QJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>CX</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>YN</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>SX</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Involvement of lateral habenula α1 subunit-containing GABAA receptor-mediated inhibitory transmission in the regulation of depression-related behaviors in experimental Parkinson's disease</article-title>
<source/>Neuropharmacology
          <year>2017</year>
<volume>116</volume>
<fpage>399</fpage>
<lpage>411</lpage>
<pub-id pub-id-type="pmid">28109827</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brichta</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Flajolet</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems</article-title>
<source/>Trends Neurosci
          <year>2013</year>
<volume>36</volume>
<fpage>543</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="pmid">23876424</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McGeer</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>McGeer</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Glial reactions in Parkinson's disease</article-title>
<source/>Mov Disord
          <year>2008</year>
<volume>23</volume>
<fpage>474</fpage>
<lpage>483</lpage>
<pub-id pub-id-type="pmid">18044695</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<collab>Alzheimer's Association</collab>
<article-title>2016 Alzheimer's disease facts and figures</article-title>
<source/>Alzheimers Dement
          <year>2016</year>
<volume>12</volume>
<fpage>459</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="pmid">27570871</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gearing</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model</article-title>
<source/>Nat Commun
          <year>2014</year>
<volume>5</volume>
<fpage>4159</fpage>
<pub-id pub-id-type="pmid">24923909</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Strooper</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Karran</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The cellular phase of Alzheimer's disease</article-title>
<source/>Cell
          <year>2016</year>
<volume>164</volume>
<fpage>603</fpage>
<lpage>615</lpage>
<pub-id pub-id-type="pmid">26871627</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yarishkin</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kowall</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease</article-title>
<source/>Nat Med
          <year>2014</year>
<volume>20</volume>
<fpage>886</fpage>
<lpage>896</lpage>
<pub-id pub-id-type="pmid">24973918</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Implications of GABAergic neurotransmission in Alzheimer's disease</article-title>
<source/>Front Aging Neurosci
          <year>2016</year>
<volume>8</volume>
<fpage>31</fpage>
<pub-id pub-id-type="pmid">26941642</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osborn</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kamphuis</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wadman</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Hol</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Astrogliosis: an integral player in the pathogenesis of Alzheimer's disease</article-title>
<source/>Prog Neurobiol
          <year>2016</year>
<volume>144</volume>
<fpage>121</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">26797041</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<collab>Australian Brain Alliance Steering Committee. Electronic address: richards@uq.edu.au</collab>
<collab>Australian Brain Alliance Steering Committee</collab>
<article-title>Australian brain alliance</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>597</fpage>
<lpage>600</lpage>
<pub-id pub-id-type="pmid">27810000</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jabalpurwala</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Brain Canada: one brain one community</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>601</fpage>
<lpage>606</lpage>
<pub-id pub-id-type="pmid">27810001</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Okano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Yamamori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Iriki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shimogori</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyawaki</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Brain/MINDS: a Japanese national brain project for marmoset neuroscience</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>582</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="pmid">27809998</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poo</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>NY</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>ZQ</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>China brain project: basic neuroscience, brain diseases, and brain-inspired computing</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>591</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="pmid">27809999</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amunts</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ebell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Telefont</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Knoll</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lippert</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>The human brain project: creating a European research infrastructure to decode the human brain</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>574</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="pmid">27809997</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hur</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Choe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koo</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Rah</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Korea brain initiative: integration and control of brain functions</article-title>
<source/>Neuron
          <year>2016</year>
<volume>92</volume>
<fpage>607</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="pmid">27810002</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiLuca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olesen</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The cost of brain diseases: a burden or a challenge?</article-title>
<source/>Neuron
          <year>2014</year>
<volume>82</volume>
<fpage>1205</fpage>
<lpage>1208</lpage>
<pub-id pub-id-type="pmid">24945765</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Berglund</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Demler</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Merikangas</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication</article-title>
<source/>Arch Gen Psychiatry
          <year>2005</year>
<volume>62</volume>
<fpage>593</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="pmid">15939837</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niccoli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Partridge</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Ageing as a risk factor for disease</article-title>
<source/>Curr Biol
          <year>2012</year>
<volume>22</volume>
<fpage>R741</fpage>
<lpage>R752</lpage>
<pub-id pub-id-type="pmid">22975005</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanchar</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Dodson</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Otis</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Wallner</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Alcohol-induced motor impairment caused by increased extrasynaptic GABA(A) receptor activity</article-title>
<source/>Nat Neurosci
          <year>2005</year>
<volume>8</volume>
<fpage>339</fpage>
<lpage>345</lpage>
<pub-id pub-id-type="pmid">15696164</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cope</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Di Giovanni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fyson</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Orbán</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Errington</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Lőrincz</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Crunelli</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Enhanced tonic GABAA inhibition in typical absence epilepsy</article-title>
<source/>Nat Med
          <year>2009</year>
<volume>15</volume>
<fpage>1392</fpage>
<lpage>1398</lpage>
<pub-id pub-id-type="pmid">19966779</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" orientation="portrait" position="float">
<label>Fig. 1</label>
<caption>
<title>Three main axes of brain disease categories during a lifespan. During the course of aging, the flexibility of living organisms and their ability to regenerate neuronal cells decreases. In the early stages of life, curable developmental diseases are the rule owing to the high plasticity and capacity for regeneration that prevail during this period. As people age and became adults, various mood-associated disorders dominate as the flexibility of the brain decreases owing to the stresses and pressure of life. Finally, in the later stages, the brain is rigid, reflecting the aging of our body. People at this stage often suffer from degenerative disorders, such as dementia and movement disorders.</title>
</caption>
<graphic xlink:href="en-26-122-g001"></graphic>
</fig>
<fig id="F2" orientation="portrait" position="float">
<label>Fig. 2</label>
<caption>
<title>GABAergic signaling in pathological states. (a) In the normal state, GABA binds to the GABA<sub>A</sub> and GABA<sub>B</sub> receptor, thereby suppressing postsynaptic neurons. The GABA transporter (GAT) also transfers synaptic and extrasynaptic GABA into astrocytes. (b) If GABA<sub>A</sub> receptor subunits are mutated, the GABA<sub>A</sub> receptor cannot be activated appropriately by GABA. Because the GABA<sub>A</sub> receptor is the player that most affects post-synaptic neurons, mutations of its subunits cause postsynaptic neurons to function abnormally. (c) GABA<sub>A</sub> and GABA<sub>B</sub> receptors in the plasma membrane of nerve cells operate over an appropriate density range; as their density decreases, the activity of GABA-bound receptors is decreased and synaptic function become abnormal. (d) Loss of GAT function causes decreased astrocytic uptake of synaptic GABA. This leaves excess eGABA to bind to GABA<sub>A</sub> and GABA<sub>B</sub> receptors. As more receptors respond to GABA, inhibitory signaling is increased.</title>
</caption>
<graphic xlink:href="en-26-122-g002"></graphic>
</fig>
</floats-group>
</article>
</pmc-articleset>